OncoMatch/Clinical Trials/NCT05726110
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Is NCT05726110 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for relapsed or refractory acute myeloid leukemia.
Treatment: Selinexor · Homoharringtonine · Daunorubicin · Cytarabine · Granulocyte Colony-Stimulating Factor · Aclacinomycin — This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05726110 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages